Protocol Ledger

NCT06413706 · Phase II · ACTIVE NOT RECRUITING

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Interventional Phase II clinical trial protocol NCT06413706 sponsored by Eli Lilly and Company in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-25 Enrollment: 45 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06413706
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06413706
Protocol FieldVerified Registry Value
NCT IdentifierNCT06413706
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment45 participants (ESTIMATED)
Registered Start Date2024-10-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI